Savara Inc (NASDAQ:SVRA) Receives $9.17 Average Target Price from Brokerages

Shares of Savara Inc (NASDAQ:SVRA) have earned an average recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $9.17.

SVRA has been the subject of a number of recent research reports. Piper Sandler upped their price target on Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Oppenheimer upped their price target on Savara from $9.50 to $11.00 and gave the stock an “outperform” rating in a research report on Tuesday. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Savara in a research report on Monday, May 13th. Evercore ISI dropped their price objective on Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, May 16th. Finally, JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of Savara in a research note on Monday, May 6th.

Savara Price Performance

Shares of SVRA opened at $4.17 on Tuesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 14.90 and a current ratio of 14.90. The stock has a 50 day simple moving average of $4.76 and a 200 day simple moving average of $4.59. Savara has a 52-week low of $2.51 and a 52-week high of $5.70. The firm has a market capitalization of $576.25 million, a PE ratio of -11.27 and a beta of 0.73.

Savara (NASDAQ:SVRA) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.02. Sell-side analysts predict that Savara will post -0.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co bought a new position in Savara during the 1st quarter worth $35,000. AJOVista LLC bought a new position in Savara during the 4th quarter worth $40,000. Principal Financial Group Inc. bought a new position in Savara during the 3rd quarter worth $48,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Savara during the 3rd quarter worth $64,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of Savara during the 4th quarter worth $74,000. Institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.